The impact of metabolic syndrome on the outcomes of transurethral resection of the prostate.

Purpose: To investigate the effect of metabolic syndrome (MS) and its components on the outcomes of transurethral resection of the prostate (TURP).

Patients And Methods: Fifty patients with MS and 50 without MS were enrolled for the study. Patients without MS were assigned to Group 1 and patients with MS were in Group 2. Patients were evaluated by the International Prostate Symptom Score (IPSS), Quality of Life index (QoL), maximum urine flow rate (Qmax), prostate-specific antigen level, and urinary ultrasonography. Six months after surgery, patients were again evaluated by IPSS and uroflowmetry; then comparison was made between the groups with respect to IPSS, QoL, and Qmax.

Results: Postoperative IPSS was determined as 11.2±0.87 in Group 1 and 12.9±0.88 in Group 2 (P<0.05). Postoperative Qmax values were determined as 18.2±0.81 and 13.9±1.12 for the two groups, respectively (P<0.05). After multivariate analyses, elevated fasting glucose (EFG) and dyslipidemia were determined to have a significant correlation with IPSS improvement. EFG and hypertension had a significant negative impact on Qmax, and hypertension and abdominal obesity had a significant correlation with QoL improvement.

Conclusions: MS as a comorbidity seems to diminish the effects of TURP. Further well-designed prospective, randomized studies with larger cohorts are needed to confirm the findings of this study.